WuXi Biologics is trading at HK$54.20, down 4.41%, with no clear company-specific announcement identified to explain the decline. - On October 7, renewed oil-price gains and inflation and interest-rate concerns weighed on Hong Kong shares; healthcare and technology stocks were among the weaker groups. - Rising bond yields and geopolitical concerns around energy supplies added to the macro backdrop; the Hang Seng Index fell 0.6% on October 7. These factors are consistent with wider risk-off pressure but do not establish a WuXi-specific catalyst.